ASX Announcement **27 July 2020**

Atomo to present at IRD Invest Virtual Investor Conference

SYDNEY Australia Monday, 27 July 2020 – Australian rapid blood test company Atomo Diagnostics Limited (ASX: AT1) (**Atomo**) is pleased to announce that Managing Director & CEO, John Kelly, will present at the IRD Invest virtual investor conference on Wednesday, 29 July 2020 at 11.00 am AEST.

Mr Kelly will provide an update on the recent developments and future plans at Atomo.

The event is free to attend and investors are invited to register ahead of time via the following link:

https://atomodiagnostics.com/atomo-to-present-on-29-july-at-ird-invest/

Once the registration form is completed, investors will receive a confirmation email with detail on how to access the briefing.

For more information, please contact:

Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117 774

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by John Kelly, Managing Director.

About Atomo

Atomo Diagnostics Limited is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, viral vs bacterial differentiation and female health.

See more at www.atomodiagnostics.com.